Diabetes mellitus: Plasticizers and nanomaterials acting as endocrine‑disrupting chemicals (Review)

Tuculina,Mihaela Jana; Perlea,Paula; Gheorghiță,Mircea; Cumpătă,Cristian Niky; Dascălu,Ionela Teodora; Turcu,Adina; Nicola,Andreea Gabriela; Gheorghiță,Lelia Mihaela; Diaconu,Oana Andreea; Valea,Ana; Ghemigian,Adina; Carsote,Mara

doi:10.3892/etm.2022.11217

Diabetes mellitus: Plasticizers and nanomaterials acting as endocrine‑disrupting chemicals (Review)

Authors:
- Mihaela Jana Tuculina
- Paula Perlea
- Mircea Gheorghiță
- Cristian Niky Cumpătă
- Ionela Teodora Dascălu
- Adina Turcu
- Andreea Gabriela Nicola
- Lelia Mihaela Gheorghiță
- Oana Andreea Diaconu
- Ana Valea
- Adina Ghemigian
- Mara Carsote
View Affiliations

Affiliations: Department of Orthodontics, Faculty of Dental Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Endodontology, Faculty of Dental Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Faculty of Dental Medicine, ‘Titu Maiorescu’ University of Bucharest, 031593 Bucharest, Romania, Departement of Endocrinology, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400337 Cluj‑Napoca, Romania, Department of Endocrinology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania
Published online on: February 16, 2022 https://doi.org/10.3892/etm.2022.11217
Article Number: 288

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Various plasticizers and nanomaterials have been linked to endocrine disruptors or endocrine‑disrupting chemicals (EDCs) which represent a large, heterogeneous, yet incompletely understood group of structures acting on normal and pathological body pathways such as hormonal production, secretion, transport and receptor binding. By contrast, various applications of nanoparticles are currently under investigation since the delivery of useful drugs, particularly insulin in diabetes mellitus, is essential in case of insulin deficiency. The aim of the present review was to introduce and examine different plasticizers and nanomaterials with potential applications for diabetic patients (such as selenium or gold‑based nanoparticles that help the oral delivery of insulin) or plasticizers/nanomaterials acting similarly to EDCs in relation to the human and animal body, particularly glucose metabolism impairment such as diabetes mellitus (DM). Bisphenol A is a chemical used worldwide; however, the effect of exposure varies with regard to the source, environment, time of exposure and the age of the organism. Daily exposure is mostly related to food and drinks stored in polycarbonate plastics. However, exposure may also be through the skin or through the maternal placenta or breast milk which are risk factors for the fetus and for the newborn. It exerts an estrogen‑like profile, but it also induces insulin resistance by impairing peripheral insulin receptors or it decreases insulin secretion by acting at the level of insulin‑secreting pancreatic β‑cells. Phthalates, compounds of flexible plastics, act as EDCs via their human metabolites such as diethyl phthalate and derivative monoethyl phthalate. Their role in inducing gestational DM and weight gain/obesity during pregnancy has been showcased. The vast field of plasticizers and nanomolecules acting as endocrine disruptors is widely linked to clinical aspects of DM, a serious condition with a major population impact. The importance of understanding and using these agents and applications is reflected in saving numerous human lives.

View Figures

View References

1	Buoso E, Masi M, Racchi M and Corsini E: Endocrine-Disrupting Chemicals' (EDCs) effects on tumour microenvironment and cancer progression: Emerging contribution of RACK1. Int J Mol Sci. 21(9229)2020.PubMed/NCBI View Article : Google Scholar
2	González-Davis O, Chauhan K, Zapian-Merino SJ and Vazquez-Duhalt R: Bi-enzymatic virus-like bionanoreactors for the transformation of endocrine disruptor compounds. Int J Biol Macromol. 146:415–421. 2020.PubMed/NCBI View Article : Google Scholar
3	Pellerin E, Caneparo C, Chabaud S, Bolduc S and Pelletier M: Endocrine-disrupting effects of bisphenols on urological cancers. Environ Res. 195(110485)2021.PubMed/NCBI View Article : Google Scholar
4	Leso V, Fontana L, Marinaccio A, Leopold K, Fanali C, Lucchetti D, Sgambato A and Iavicoli I: Sub-chronic palladium nanoparticle effects on the endocrine reproductive system of female Wistar rats: Preliminary data. Toxicol Ind Health. 35:403–409. 2019.PubMed/NCBI View Article : Google Scholar
5	Jaffrezic-Renault N, Kou J, Tan D and Guo Z: New trends in the electrochemical detection of endocrine disruptors in complex media. Anal Bioanal Chem. 412:5913–5923. 2020.PubMed/NCBI View Article : Google Scholar
6	American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1):S14–S31. 2020.PubMed/NCBI View Article : Google Scholar
7	Radu L, Carsote M, Gheorghisan-Galateanu AA, Preda SA, Calborean V, Stanescu R, Gheorman V and Albulescu DM: Blood parathyrin and mineral metabolism dinamics: A clinical analyze. Rev Chim. 69:2754–2758. 2018.
8	Zimmet PZ: Diabetes and its drivers: The largest epidemic in human history? Clin Diabetes Endocrinol. 3(1)2017.PubMed/NCBI View Article : Google Scholar
9	Zheng Y, Ley SH and Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 14:88–98. 2018.PubMed/NCBI View Article : Google Scholar
10	Vann R, Bussuan RM, Rombaldi RL and Arbex AK: Endocrine disruptors and the induction of insulin resistance. Curr Diabetes Rev. 17(e102220187107)2021.PubMed/NCBI View Article : Google Scholar
11	Bai Q, Han K, Dong K, Zheng C, Zhang Y, Long Q and Lu T: Potential applications of nanomaterials and technology for diabetic wound healing. Int J Nanomedicine. 15:9717–9743. 2020.PubMed/NCBI View Article : Google Scholar
12	Kaur P and Khatik G: An overview of computer-aided drug design tools and recent applications in designing of antidiabetic agents. Curr Drug Targets. 22:1158–1182. 2021.PubMed/NCBI View Article : Google Scholar
13	Al-Quraishy S, Dkhil MA and Abdel Moneim AE: Anti-hyperglycemic activity of selenium nanoparticles in streptozotocin-induced diabetic rats. Int J Nanomedicine. 10:6741–6756. 2015.PubMed/NCBI View Article : Google Scholar
14	Khurana A, Tekula S, Saifi MA, Venkatesh P and Godugu C: Therapeutic applications of selenium nanoparticles. Biomed Pharmacother. 111:802–812. 2019.PubMed/NCBI View Article : Google Scholar
15	Deng W, Xie Q, Wang H, Ma Z, Wu B and Zhang X: Selenium nanoparticles as versatile carriers for oral delivery of insulin: Insight into synergic antidiabetic effect and mechanism. Nanomedicine. 13:1965–1974. 2017.PubMed/NCBI View Article : Google Scholar
16	Kumari S, Kamboj VK, Rajpoot D, Teotia AK, Verma PK and Singh GN: The Unprecedented role of gold nanomaterial in diabetes management. Recent Pat Drug Deliv Formul. 13:219–227. 2019.PubMed/NCBI View Article : Google Scholar
17	Mohsen AM: Nanothecnology advanced strategies for the management of diabetes mellitus. Curr Drug Targets. 20:995–1007. 2019.PubMed/NCBI View Article : Google Scholar
18	Kumari Y, Singh SK, Kumar R, Kumar B, Kaur G, Gulati M, Tewari D, Gowthamarajan K, Karri VVSNR, Ayinkamiye C, et al: Modified apple polysaccharide capped gold nanoparticles for oral delivery of insulin. Int J Biol Macromol. 149:976–988. 2020.PubMed/NCBI View Article : Google Scholar
19	Hou L, Zheng Y, Wang Y, Hu Y, Shi J, Liu Q, Zhang H and Zhang Z: Self-Regulated carboxyphenylboronic acid-modified mesoporous silica nanoparticles with ‘touch switch’ releasing property for insulin delivery. ACS Appl Mater Interfaces. 10:21927–21938. 2018.PubMed/NCBI View Article : Google Scholar
20	Zou Z, He D, Cai L, He X, Wang K, Yang X, Li L, Li S and Su X: Alizarin complexone functionalized mesoporous silica nanoparticles: A smart system integrating glucose-responsive double-drugs release and real-time monitoring capabilities. ACS Appl Mater Interfaces. 8:8358–8366. 2016.PubMed/NCBI View Article : Google Scholar
21	Iorga RA, Bacalbasa N, Carsote M, Bratu OG, Stanescu AMA, Bungau S, Pantis C and Diaconu CC: Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med. 20:2396–2400. 2020.PubMed/NCBI View Article : Google Scholar
22	Presas E, Tovar S, Cuñarro J, O'shea JP and O'driscoll CM: Pre-Clinical evaluation of a modified cyclodextrin-based nanoparticle for intestinal delivery of liraglutide. J Pharm Sci. 110:292–300. 2021.PubMed/NCBI View Article : Google Scholar
23	Lee YH, Hong YL and Wu TL: Novel silver and nanoparticle-encapsulated growth factor co-loaded chitosan composite hydrogel with sustained antimicrobility and promoted biological properties for diabetic wound healing. Mater Sci Eng C Mater Biol Appl. 118(111385)2021.PubMed/NCBI View Article : Google Scholar
24	Yang L, Zhang L, Hu J, Wang W and Liu X: Promote anti-inflammatory and angiogenesis using a hyaluronic acid-based hydrogel with miRNA-laden nanoparticles for chronic diabetic wound treatment. Int J Biol Macromol. 166:166–178. 2021.PubMed/NCBI View Article : Google Scholar
25	Hu H, Fan X, Guo Q, Wei X, Yang D, Zhang B, Liu J, Wu Q, Oh Y, Feng Y, et al: Silicon dioxide nanoparticles induce insulin resistance through endoplasmic reticulum stress and generation of reactive oxygen species. Part Fibre Toxicol. 16(41)2019.PubMed/NCBI View Article : Google Scholar
26	Rosenfeld CS: Gut dysbiosis in animals due to environmental chemical exposures. Front Cell Infect Microbiol. 7(396)2017.PubMed/NCBI View Article : Google Scholar
27	Farrugia F, Aquilina A, Vassallo J and Pace NP: Bisphenol a and type 2 diabetes mellitus: A review of epidemiologic, functional, and early life factors. Int J Environ Res Public Health. 18(716)2021.PubMed/NCBI View Article : Google Scholar
28	Bakoyiannis I, Kitraki E and Stamatakis A: Endocrine-disrupting chemicals and behaviour: A high risk to take? Best Pract Res Clin Endocrinol Metab. 35(101517)2021.PubMed/NCBI View Article : Google Scholar
29	Khan NG, Correia J, Adiga D, Rai PS, Dsouza HS, Chakrabarty S and Kabekkodu SP: A comprehensive review on the carcinogenic potential of bisphenol A: Clues and evidence. Environ Sci Pollut Res Int. 28:19643–19663. 2021.PubMed/NCBI View Article : Google Scholar
30	Vom Saal FS and Vandenberg LN: Update on the health effects of bisphenol A: Overwhelming evidence of harm. Endocrinology. 162(bqaa171)2021.PubMed/NCBI View Article : Google Scholar
31	Campbell JE and Newgard CB: Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol. 22:142–158. 2021.PubMed/NCBI View Article : Google Scholar
32	Wei Q, Qi L, Lin H, Liu D, Zhu X, Dai Y, Waldron RT, Lugea A, Goodarzi MO, Pandol SJ and Li L: Pathological mechanisms in diabetes of the exocrine pancreas: What's known and what's to know. Front Physiol. 11(570276)2020.PubMed/NCBI View Article : Google Scholar
33	Marraudino M, Bonaldo B, Farinetti A, Panzica G, Ponti G and Gotti S: Metabolism disrupting chemicals and alteration of neuroendocrine circuits controlling food intake and energy metabolism. Front Endocrinol (Lausanne). 9(766)2019.PubMed/NCBI View Article : Google Scholar
34	Nadal A, Quesada I, Tudurí E, Nogueiras R and Alonso-Magdalena P: Endocrine-disrupting chemicals and the regulation of energy balance. Nat Rev Endocrinol. 13:536–546. 2017.PubMed/NCBI View Article : Google Scholar
35	Graceli JB, Dettogni RS, Merlo E, Niño O, Da Costa CS, Zanol JF, Ríos Morris EA, Miranda-Alves L and Denicol AC: The impact of endocrine-disrupting chemical exposure in the mammalian hypothalamic-pituitary axis. Mol Cell Endocrinol. 518(110997)2020.PubMed/NCBI View Article : Google Scholar
36	Cocolos AM, Dumitru N, Petrova EN, Cocolos I, Tiglis M, Dragomirescu RFI, Olaru M, Dumitru A and Ghemigian AM: Endocrine disrupting chemicals-the X factor in different pathologies. Rev Chim. 69:136–139. 2018.
37	Murphy L, Mérida-Ortega Á, Cebrián ME, Hernández-Garciadiego L, Gómez-Ruiz H, Gamboa-Loira B and López-Carrillo L: Exposure to bisphenol A and diabetes risk in Mexican women. Environ Sci Pollut Res Int. 26:26332–26338. 2019.PubMed/NCBI View Article : Google Scholar
38	Battal D, Cok I, Unlusayin I, Aktas A and Tunctan B: Determination of urinary levels of Bisphenol A in a Turkish population. Environ Monit Assess. 186:8443–8452. 2014.PubMed/NCBI View Article : Google Scholar
39	Caban M and Stepnowski P: The quantification of bisphenols and their analogues in wastewaters and surface water by an improved solid-phase extraction gas chromatography/mass spectrometry method. Environ Sci Pollut Res Int. 27:28829–28839. 2020.PubMed/NCBI View Article : Google Scholar
40	Kahn LG, Philippat C, Nakayama SF, Slama R and Trasande L: Endocrine-disrupting chemicals: Implications for human health. Lancet Diabetes Endocrinol. 8:703–718. 2020.PubMed/NCBI View Article : Google Scholar
41	Lee MR, Kim JH, Choi YH, Bae S, Park C and Hong YC: Association of bisphenol A exposure with overweight in the elderly: A panel study. Environ Sci Pollut Res Int. 22:9370–9377. 2015.PubMed/NCBI View Article : Google Scholar
42	Mileva G, Baker SL, Konkle AT and Bielajew C: Bisphenol-A: Epigenetic reprogramming and effects on reproduction and behavior. Int J Environ Res Public Health. 11:7537–7561. 2014.PubMed/NCBI View Article : Google Scholar
43	Velmurugan G, Ramprasath T, Gilles M, Swaminathan K and Ramasamy S: gut microbiota, endocrine-disrupting chemicals, and the diabetes epidemic. Trends Endocrinol Metab. 28:612–625. 2017.PubMed/NCBI View Article : Google Scholar
44	James-Todd TM, Meeker JD, Huang T, Hauser R, Ferguson KK, Rich-Edwards JW, Mcelrath TF and Seely EW: Pregnancy urinary phthalate metabolite concentrations and gestational diabetes risk factors. Environ Int. 96:118–126. 2016.PubMed/NCBI View Article : Google Scholar
45	Chevalier N and Fénichel P: Endocrine disruptors: New players in the pathophysiology of type 2 diabetes? Diabetes Metab. 41:107–115. 2015.PubMed/NCBI View Article : Google Scholar
46	Shaffer RM, Ferguson KK, Sheppard L, James-Todd T, Butts S, Chandrasekaran S, Swan SH, Barrett ES, Nguyen R, Bush N, et al: Study team. Maternal urinary phthalate metabolites in relation to gestational diabetes and glucose intolerance during pregnancy. Environ Int. 123:588–596. 2019.PubMed/NCBI View Article : Google Scholar
47	Zukin H, Eskenazi B, Holland N and Harley KG: Prenatal exposure to phthalates and maternal metabolic outcomes in a high-risk pregnant Latina population. Environ Res. 194(110712)2021.PubMed/NCBI View Article : Google Scholar
48	Chen M, Zhao S, Guo WH, Zhu YP, Pan L, Xie ZW, Sun WI and Jiang JT: Maternal exposure to Di-n-butyl phthalate (DBP) aggravate gestational diabetes mellitus via FoxM1 suppression by pSTAT1 signalling. Ecotoxicol Environ Saf. 205(111154)2020.PubMed/NCBI View Article : Google Scholar
49	Rolfo A, Nuzzo AM, De Amicis R, Moretti L, Bertoli S and Leone A: Fetal-maternal exposure to endocrine disruptors: Correlation with diet intake and pregnancy outcomes. Nutrients. 12(1744)2020.PubMed/NCBI View Article : Google Scholar
50	Feng W, Liu Y, Ding Y, Mao G, Zhao T, Chen K, Qiu X, Xu T, Zhao X, Wu X and Yang L: Typical neurobehavioral methods and transcriptome analysis reveal the neurotoxicity and mechanisms of di(2-ethylhexyl) phthalate on pubertal male ICR mice with type 2 diabetes mellitus. Arch Toxicol. 94:1279–1302. 2020.PubMed/NCBI View Article : Google Scholar